Neurogene (NGNE)
Neurogene on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq.
5.1M
Short interest
settlement 2026-10-15
14.4
Days to cover
+2.6 days vs prior
64.4%
Short share of volume
2026-11-02
88
Fails to deliver
settlement 2026-10-14
Thu 12 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in NGNE is 5,093,623 shares, up 1,813,451 shares over the last month. Over the last 48 readings it ranged from 914,186 shares (31 October 2024) to 5,093,623 shares (15 October 2026). The latest reading sits at the top of that range. At the reported average volume of 355K shares a day that is 14.4 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/ngne" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 5,093,623 | +2.4% | 354,650 | 14.36 |
| 2026-09-30 | 4,974,749 | +51.7% | 423,989 | 11.73 |
| 2026-09-15 | 3,280,172 | +4.6% | 194,657 | 16.85 |
| 2026-08-31 | 3,135,369 | +3.2% | 230,841 | 13.58 |
| 2026-08-14 | 3,038,441 | +1.1% | 180,803 | 16.81 |
| 2026-07-31 | 3,005,232 | +2.6% | 186,066 | 16.15 |
| 2026-07-15 | 2,928,178 | -12.7% | 386,893 | 7.57 |
| 2026-06-30 | 3,352,320 | -5.5% | 248,662 | 13.48 |
| 2026-06-15 | 3,548,175 | +0.1% | 154,684 | 22.94 |
| 2026-05-29 | 3,545,963 | -1.6% | 129,045 | 27.48 |
| 2026-05-15 | 3,603,655 | -3.1% | 146,197 | 24.65 |
| 2026-04-30 | 3,720,441 | -7.3% | 187,448 | 19.85 |
| 2026-04-15 | 4,011,809 | -0.4% | 140,085 | 28.64 |
| 2026-03-31 | 4,029,257 | +3.7% | 159,977 | 25.19 |
| 2026-03-13 | 3,885,559 | +5.8% | 195,122 | 19.91 |
| 2026-02-27 | 3,673,771 | +1.9% | 235,342 | 15.61 |
| 2026-02-13 | 3,605,074 | +0.4% | 110,413 | 32.65 |
| 2026-01-30 | 3,591,099 | +1.6% | 112,650 | 31.88 |
| 2026-01-15 | 3,536,210 | +1.0% | 175,308 | 20.17 |
| 2025-12-31 | 3,502,155 | -1.0% | 193,307 | 18.12 |
| 2025-12-15 | 3,538,773 | +7.7% | 193,412 | 18.30 |
| 2025-11-28 | 3,285,408 | -0.9% | 208,609 | 15.75 |
| 2025-11-14 | 3,315,140 | +16.6% | 301,508 | 11.00 |
| 2025-10-31 | 2,844,441 | -0.5% | 217,868 | 13.06 |
| 2025-10-15 | 2,858,834 | +0.8% | 296,369 | 9.65 |
| 2025-09-30 | 2,835,224 | +0.4% | 149,099 | 19.02 |
| 2025-09-15 | 2,823,152 | +3.1% | 170,432 | 16.56 |
| 2025-08-29 | 2,738,272 | +3.0% | 94,659 | 28.93 |
| 2025-08-15 | 2,659,151 | +2.5% | 122,984 | 21.62 |
| 2025-07-31 | 2,593,492 | +1.6% | 117,197 | 22.13 |
| 2025-07-15 | 2,553,365 | +15.4% | 275,471 | 9.27 |
| 2025-06-30 | 2,212,244 | -1.5% | 178,965 | 12.36 |
| 2025-06-13 | 2,245,516 | -6.2% | 220,607 | 10.18 |
| 2025-05-30 | 2,393,875 | -11.2% | 173,155 | 13.83 |
| 2025-05-15 | 2,696,233 | -8.8% | 251,105 | 10.74 |
| 2025-04-30 | 2,954,822 | +3.3% | 228,880 | 12.91 |
| 2025-04-15 | 2,860,015 | +17.4% | 454,576 | 6.29 |
| 2025-03-31 | 2,437,058 | +11.8% | 279,353 | 8.72 |
| 2025-03-14 | 2,179,819 | +11.1% | 195,303 | 11.16 |
| 2025-02-28 | 1,961,824 | +12.0% | 155,774 | 12.59 |
| 2025-02-14 | 1,751,062 | -12.7% | 328,515 | 5.33 |
| 2025-01-31 | 2,005,059 | +10.0% | 225,367 | 8.90 |
| 2025-01-15 | 1,823,209 | +0.3% | 203,086 | 8.98 |
| 2024-12-31 | 1,817,476 | +13.5% | 259,507 | 7.00 |
| 2024-12-13 | 1,600,807 | +36.3% | 341,088 | 4.69 |
| 2024-11-29 | 1,174,623 | -28.4% | 984,502 | 1.19 |
| 2024-11-15 | 1,640,330 | +79.4% | 552,626 | 2.97 |
| 2024-10-31 | 914,186 | -2.2% | 97,027 | 9.42 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of NGNE volume is 64.4%, up 12.7 points over the last five sessions. Over the last 30 readings it ranged from 21.5% (12 October 2026) to 97.2% (22 September 2026). The latest reading is 3.0 points below the 30-session average of 67.4%, on 71K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 46K | 71K | 64.4% | 0 |
| 2026-10-30 | 59K | 82K | 72.8% | 0 |
| 2026-10-29 | 54K | 103K | 52.0% | 0 |
| 2026-10-28 | 155K | 253K | 61.4% | 0 |
| 2026-10-27 | 170K | 210K | 80.8% | 660 |
| 2026-10-26 | 24K | 47K | 51.7% | 0 |
| 2026-10-23 | 27K | 48K | 56.1% | 0 |
| 2026-10-22 | 40K | 85K | 46.9% | 0 |
| 2026-10-21 | 268K | 304K | 88.3% | 0 |
| 2026-10-20 | 55K | 76K | 72.7% | 0 |
| 2026-10-19 | 42K | 93K | 45.6% | 0 |
| 2026-10-16 | 167K | 211K | 79.1% | 0 |
| 2026-10-15 | 265K | 318K | 83.4% | 0 |
| 2026-10-14 | 152K | 196K | 77.4% | 5,800 |
| 2026-10-13 | 61K | 121K | 50.0% | 248 |
| 2026-10-12 | 39K | 183K | 21.5% | 0 |
| 2026-10-09 | 62K | 144K | 43.4% | 0 |
| 2026-10-08 | 93K | 181K | 51.3% | 0 |
| 2026-10-07 | 32K | 42K | 75.5% | 0 |
| 2026-10-06 | 37K | 46K | 80.7% | 0 |
| 2026-10-05 | 73K | 92K | 79.5% | 921 |
| 2026-10-02 | 103K | 147K | 69.8% | 0 |
| 2026-10-01 | 42K | 53K | 79.3% | 0 |
| 2026-09-30 | 54K | 61K | 89.6% | 0 |
| 2026-09-29 | 66K | 76K | 87.0% | 0 |
| 2026-09-28 | 28K | 48K | 58.2% | 0 |
| 2026-09-25 | 50K | 72K | 69.5% | 0 |
| 2026-09-24 | 174K | 228K | 76.3% | 622 |
| 2026-09-23 | 67K | 109K | 61.8% | 663 |
| 2026-09-22 | 925K | 952K | 97.2% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 14 October 2026, the fails-to-deliver balance in NGNE is 88 shares, up 68 shares over the last settlement date. Over the last 30 readings it ranged from 2 shares (2 September 2026) to 6,760 shares (30 April 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-14 | 88 | $21.56 | $2K |
| 2026-10-13 | 20 | $24.44 | $489 |
| 2026-10-09 | 500 | $26.50 | $13K |
| 2026-10-07 | 503 | $25.45 | $13K |
| 2026-10-02 | 16 | $26.55 | $425 |
| 2026-09-24 | 61 | $30.93 | $2K |
| 2026-09-21 | 854 | $32.09 | $27K |
| 2026-09-18 | 4,000 | $32.41 | $130K |
| 2026-09-14 | 117 | $35.48 | $4K |
| 2026-09-11 | 49 | $36.12 | $2K |
| 2026-09-04 | 1,238 | $37.61 | $47K |
| 2026-09-02 | 2 | $37.87 | $76 |
| 2026-08-31 | 483 | $36.58 | $18K |
| 2026-08-27 | 124 | $38.41 | $5K |
| 2026-08-19 | 5 | $35.67 | $178 |
| 2026-08-03 | 24 | $32.89 | $789 |
| 2026-07-30 | 41 | $33.66 | $1K |
| 2026-07-17 | 103 | $36.50 | $4K |
| 2026-07-15 | 66 | $39.08 | $3K |
| 2026-07-09 | 3,889 | $38.24 | $149K |
| 2026-07-01 | 43 | $31.45 | $1K |
| 2026-06-22 | 2,923 | $31.53 | $92K |
| 2026-06-17 | 9 | $29.35 | $264 |
| 2026-06-12 | 4 | $29.00 | $116 |
| 2026-06-08 | 58 | $26.49 | $2K |
| 2026-06-02 | 959 | $27.54 | $26K |
| 2026-05-20 | 134 | $26.88 | $4K |
| 2026-05-19 | 396 | $27.98 | $11K |
| 2026-04-30 | 6,760 | $26.48 | $179K |
| 2026-04-27 | 2,068 | $27.03 | $56K |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for NGNE in the last 90 days. The most recent filings are listed below. Latest filing: McMinn Rachel (Chief Executive Officer) on 2026-09-22.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-22 | McMinn Rachel | Chief Executive Officer | Exercise or conversion | 756 | $25.32 | $19K | 1.3M |
| 2026-07-07 | Cvijic Christine Mikail | President and CFO | Sell | 4K | $36.13 | $152K | 84K |
| 2026-07-06 | Cvijic Christine Mikail | President and CFO | Sell | 600 | $36.02 | $22K | 88K |
| 2026-07-02 | Cvijic Christine Mikail | President and CFO | Sell | 2K | $35.23 | $54K | 89K |
| 2026-07-02 | Cvijic Christine Mikail | President and CFO | Sell | 3K | $34.58 | $88K | 90K |
| 2026-07-01 | Cvijic Christine Mikail | President and CFO | Sell | 739 | $34.06 | $25K | 93K |
| 2026-05-06 | Cvijic Christine Mikail | President and CFO | Sell | 5K | $32.44 | $156K | 94K |
| 2026-05-06 | Cvijic Christine Mikail | President and CFO | Sell | 5K | $30.07 | $144K | 98K |
| 2026-03-26 | McMinn Rachel | Chief Executive Officer | Sell | 3K | $22.07 | $74K | 1.3M |
| 2026-03-26 | Jordan Julie | Chief Medical Officer | Sell | 828 | $21.89 | $18K | 12K |
| 2026-03-26 | Cvijic Christine Mikail | President and CFO | Sell | 3K | $21.62 | $55K | 103K |
| 2026-03-13 | Cvijic Christine Mikail | President and CFO | Sell | 263 | $22.02 | $6K | 106K |
| 2026-03-13 | Cvijic Christine Mikail | President and CFO | Sell | 1K | $21.25 | $30K | 106K |
| 2026-03-13 | Cvijic Christine Mikail | President and CFO | Sell | 2K | $20.42 | $49K | 107K |
| 2026-03-13 | Cobb Stuart | Chief Scientific Officer | Sell | 148 | $22.08 | $3K | 30K |
| 2026-03-13 | Cobb Stuart | Chief Scientific Officer | Sell | 3K | $21.34 | $57K | 31K |
| 2026-03-13 | Cobb Stuart | Chief Scientific Officer | Sell | 4K | $20.41 | $81K | 33K |
| 2026-02-27 | Cvijic Christine Mikail | President and CFO | Sell | 5K | $25.11 | $121K | 110K |
| 2026-02-20 | McMinn Rachel | Chief Executive Officer | Grant | 26K | $0.00 | $0 | 1.3M |
| 2026-02-20 | Jordan Julie | Chief Medical Officer | Grant | 5K | $0.00 | $0 | 13K |
| 2026-02-20 | Cvijic Christine Mikail | President and CFO | Grant | 22K | $0.00 | $0 | 115K |
| 2026-02-20 | Cobb Stuart | Chief Scientific Officer | Grant | 17K | $0.00 | $0 | 37K |
| 2025-05-14 | Cobb Stuart | Chief Scientific Officer | Sell | 7K | $15.15 | $103K | 21K |
| 2025-03-26 | McMinn Rachel | Chief Executive Officer | Grant | 24K | $0.00 | $0 | 1.3M |
| 2025-03-26 | Jordan Julie | Chief Medical Officer | Grant | 8K | $0.00 | $0 | 8K |
| 2025-03-26 | Cvijic Christine Mikail | President and CFO | Grant | 20K | $0.00 | $0 | 93K |
| 2025-03-26 | Cobb Stuart | Chief Scientific Officer | Grant | 7K | $0.00 | $0 | 28K |
| 2025-03-13 | Cvijic Christine Mikail | President and CFO | Sell | 5K | $16.94 | $76K | 72K |
| 2024-11-26 | AKKARAJU SRINIVAS | TenPercentOwner | Buy | 21K | $24.91 | $517K | 1.7M |
| 2024-11-26 | AKKARAJU SRINIVAS | TenPercentOwner | Buy | 11K | $26.01 | $281K | 1.7M |
| 2024-11-26 | AKKARAJU SRINIVAS | TenPercentOwner | Buy | 15K | $26.73 | $407K | 1.7M |
| 2024-11-26 | AKKARAJU SRINIVAS | TenPercentOwner | Buy | 2K | $27.50 | $55K | 1.7M |
| 2024-11-22 | McMinn Rachel | Chief Executive Officer | Buy | 48K | $20.40 | $969K | 1.3M |
| 2024-11-22 | Cvijic Christine Mikail | President and CFO | Buy | 24K | $20.48 | $492K | 77K |
| 2024-03-13 | Cobb Stuart | Chief Scientific Officer | Grant | 20K | $0.00 | $0 | 20K |
| 2024-03-13 | Cvijic Christine Mikail | President and CFO | Grant | 32K | $0.00 | $0 | 53K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON2 Form 144 notices on file for NGNE worth $341K at the prices reported; 0 in the last 90 days worth $0. Latest: STUART COBB filed on 2026-03-13 to sell 6,797 shares ($152K) from 2026-03-13.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-03-13 | STUART COBBOfficer | 7K | $152K | 0.044% | 2026-03-13 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-27 | Christine CvijicOfficer | 10K | $189K | 0.062% | 2026-02-27 | J.P. Morgan Securities LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON13 holders report 5% or more of NGNE in their latest filing, all on Schedule 13G (passive). The largest reported stake is PRUDENTIAL FINANCIAL INC at 11.2% of the class (2,231,357 shares), filed 2026-10-07 for an event on 2026-09-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-07 | 13G | PRUDENTIAL FINANCIAL INCparent holding company | 2.2M | 11.2% | 2026-09-30 |
| 2026-10-06 | 13G | Jennison Associates LLCinvestment adviser | 2.2M | 11.1% | 2026-09-30 |
| 2026-08-14 | 13G/Ano. 1 | Trails Edge Biotechnology Master Fund, LPpartnership | 715K | 4.5% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Trails Edge Capital Partners, LPinvestment adviser, partnership | 715K | 4.5% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Ortav Yehudaiindividual | 715K | 4.5% | 2026-06-30 |
| 2026-08-14 | 13G | Dmitry Balyasnyparent holding company, individual | 819K | 5.2% | 2026-06-30 |
| 2026-08-14 | 13G | Dames GP LLCparent holding company, other entity | 819K | 5.2% | 2026-06-30 |
| 2026-08-14 | 13G | BALYASNY ASSET MANAGEMENT L.P.investment adviser, partnership | 819K | 5.2% | 2026-06-30 |
| 2026-08-14 | 13G | BAM GP LLCparent holding company, other entity | 819K | 5.2% | 2026-06-30 |
| 2026-08-14 | 13G | Balyasny Asset Management Holdings LPparent holding company, partnership | 819K | 5.2% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 7 | Redmile Group, LLCinvestment adviser, other entity | 1.6M | 9.9% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 7 | Jeremy C. Greenparent holding company, individual | 1.6M | 9.9% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 7 | Redmile Biopharma Investments I, L.P.partnership | 812K | 5.1% | 2026-06-30 |
| 2025-11-14 | 13G/Ano. 1 | EcoR1 Capital, LLCinvestment adviser, other entity | 1.4M | 9.9% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | Oleg Nodelmanparent holding company, individual | 1.4M | 9.9% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | EcoR1 Capital Fund Qualified, L.P.partnership | 1.2M | 8.6% | 2025-09-30 |
13F holders
Tracked managers holding NGNE at their latest 13F. JSON6 of the 30 tracked managers held NGNE at their latest 13F, $20.1M in total at quarter-end prices. Citadel Advisors is the largest at $12.9M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 4 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Citadel Advisors | 2026-06-30 | 409K | $12.9M | 0.00% | +22K |
| Point72 Asset Management | 2026-06-30 | 142K | $4.5M | 0.00% | new |
| Millennium Management | 2026-06-30 | 43K | $1.3M | 0.00% | -162K |
| Renaissance Technologies | 2026-06-30 | 20K | $642K | 0.00% | -23K |
| AQR Capital Management | 2026-06-30 | 15K | $474K | 0.00% | +5K |
| D. E. Shaw & Co. | 2026-06-30 | 10K | $308K | 0.00% | new |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Neurogene in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Neurogene (NGNE), SEC CIK 1404644, listed on Nasdaq. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-14.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-03-13.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-07.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-11.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-22.JSON and CSV
- Company record
- EDGAR filing index for CIK 1404644Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
- SYRESpyre Therapeutics
- SYYSysco
- TAT&T
- TAPMolson Coors
- TCOMTrip.com Group
- TDToronto-Dominion Bank
- TDGTransDigm Group
- TDYTeledyne Technologies
Datasets
Frequently Asked Questions
How much of NGNE is sold short?
What is NGNE's daily short volume?
Does NGNE have fails to deliver?
Are NGNE insiders buying or selling?
Have NGNE insiders filed to sell?
Who owns 5% or more of NGNE?
Which tracked 13F managers own NGNE?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.